340B Hospitals Playing 'Outsize' Medicare Role In Many Therapeutic Categories
This article was originally published in The Pink Sheet Daily
Analysis supported by drug industry adds to growing research on scale of Medicare Part B payments to hospitals receiving 340B drug discounts.
You may also be interested in...
Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.
It’s not quite the rebate rule, but final reg aims for ‘a reduction in the use of rebates and other price concessions’ driven by the transparency requirement and broad definitions. PCMA warns that ‘mandating an increased level of disclosure for this information could result in higher prescription drug prices for consumers.’
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.